Antibody Humanization Market

Antibody Humanization Market Overview

The global antibody humanization market, valued at USD 5.7 billion in 2024, is projected to reach USD 6.2 billion in 2025 and USD 14.9 billion by 2035, representing a CAGR of 9.1% during the forecast period. First discovered in 1975, monoclonal antibodies are considered to be one of the fastest growing therapy segments in the biopharmaceutical industry. In the year 2016, Humira, a monoclonal antibody, generated revenues worth more than USD 16 billion to become the highest selling drug. With a strong development pipeline and high clinical success rate, the market continues to witness increasing adoption of antibody based therapies and products.

The growing industry has faced / continues to face several challenges. One of the biggest hurdles to the growth of antibody based products has been the lack of technical know-how across different stages of drug discovery. This situation is particularly true for the more traditional pharmaceutical companies that have recently ventured into the targeted therapies domain. Some of these companies have mitigated this issue by making specific acquisitions and / or hiring trained personnel to cater to the requirements. However, several others have preferred to out-source these steps to contract services providers. In fact, over the years, a number of services providers offering antibody discovery have been established, and have grown to become an indispensable part of the biopharmaceutical market.

Certain steps of the antibody drug discovery process require advanced expertise, and companies offering these specialized services have attracted significant attention of drug / therapy developers. Two such specific services are to reduce antibody immunogenicity (humanization) and enhance its affinity (affinity maturation). Immunogenicity has continued to be one of the most limiting factors of the clinical success of antibodies. Antibody humanization has emerged as an extensively studied method for reducing antibody immunogenicity. There are several contract services providers that are providing novel technologies beyond the traditional methods to facilitate antibody humanization as well as to enhance antibody affinity. These contract services providers have enabled the drug developers to develop therapeutic antibodies with low immunogenicity and high affinity.

Recent Developments in Antibody Humanization Market

Several recent developments have taken place in the field of antibody humanization and affinity maturation. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2026, Biocytogen launched RenSuper™ AI-powered antibody discovery platform and automated manufacturing infrastructure in Beijing. The system integrates RenMice-derived fully human antibody libraries, AI-driven candidate selection, and high-throughput validation.
• In May 2026, Immunocan Biotech closed a RMB 250 million Series A funding round with an aim to expand its fully human antibody discovery platforms, gene-edited animal models, and AI-driven screening technologies.
• In March 2026, kyron.bio entered into a collaboration with Servier to apply precision glycoengineering technology to antibody therapeutics. Servier funds the program while kyron.bio optimizes glycan structures to improve antibody efficacy, safety, and scalability. The collaboration enables further development and potential expansion of engineered antibody candidates across multiple disease areas.
• In January 2026, Genmab collaborated with Anthropic to deploy agentic AI tools to accelerate antibody R&D and clinical development workflows. The collaboration focuses on improving data processing, document generation, and operational efficiency in antibody programs.
• In January 2026, Bayer collaborated with Cradle to use a machine learning protein engineering platform for antibody optimization. The partnership aims to improve lead molecule generation, potency, safety, and manufacturability in Bayer’s antibody pipeline. It reflects increasing adoption of generative AI in therapeutic antibody design and development workflows.

Scope of Antibody Humanization Market Report:

The “Antibody Humanization Market, Till 2035” report provides a comprehensive view on the current landscape and the future outlook of the antibody humanization and affinity maturation contract research services and platforms market. The study presents an in-depth analysis of a diverse set of companies that provide such services across different regions worldwide. In addition to other elements, the report covers the following:

• The current state of the antibody humanization market with respect to key players along with information on location of these companies, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing these services and the revenue / business models used.
• Elaborate profiles of established / emerging players that have expertise in providing antibody humanization and / or affinity maturation services, highlighting the methodologies adopted by these companies and their recent partnerships and collaborations in the antibody humanization and affinity maturation domain. The profiles also have a detailed future outlook section, detailing the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
• An analysis of the most active regions in terms of humanization and affinity maturation services for biologics, featuring schematic representations on world maps clearly indicating the location of active services hubs.
• A benchmark analysis to provide a means to compare existing capabilities within respective peer groups and help stakeholders in the industry to identify ways to achieve a competitive edge over contemporary players.
• A publication analysis representing recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain.
• A SWOT analysis, which elaborates on the strengths, weaknesses, opportunities and threats related to players engaged in this domain.
• A go-to-guide for outsourcing, representing different models that can be used to facilitate the decision whether companies should out-source a particular activity / operation, or not.

One of the key objectives of the antibody humanization report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as number of projects being out-sourced, number of projects undertaken per year and expected pricing, we have provided an informed estimate of the likely evolution of the opportunity for antibody humanization services providers, till 2035. The base year for the report is 2024. To account for the uncertainties associated with these services and to add robustness to our model, we have provided three forecast scenarios portraying conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in antibody humanization report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These included contributions from CSO of LakePharma, Reader in Bioinformatics and Computational Biology at University College London and General Manager of YuMab.